蛋白酶体抑制联合免疫疗法治疗多发性骨髓瘤的研究现状

IF 6.9 2区 医学 Q1 HEMATOLOGY
David Kegyes , Diana Gulei , Rares Drula , Diana Cenariu , Bogdan Tigu , Delia Dima , Alina Tanase , Sorina Badelita , Anca-Dana Buzoianu , Stefan Ciurea , Gabriel Ghiaur , Evangelos Terpos , Aaron Ciechanover , Hermann Einsele , Ciprian Tomuleasa
{"title":"蛋白酶体抑制联合免疫疗法治疗多发性骨髓瘤的研究现状","authors":"David Kegyes ,&nbsp;Diana Gulei ,&nbsp;Rares Drula ,&nbsp;Diana Cenariu ,&nbsp;Bogdan Tigu ,&nbsp;Delia Dima ,&nbsp;Alina Tanase ,&nbsp;Sorina Badelita ,&nbsp;Anca-Dana Buzoianu ,&nbsp;Stefan Ciurea ,&nbsp;Gabriel Ghiaur ,&nbsp;Evangelos Terpos ,&nbsp;Aaron Ciechanover ,&nbsp;Hermann Einsele ,&nbsp;Ciprian Tomuleasa","doi":"10.1016/j.blre.2023.101100","DOIUrl":null,"url":null,"abstract":"<div><p><span>Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of all neoplastic diseases. Nowadays, clinicians have a broad arsenal of </span>drugs<span><span><span><span><span> at their disposal for the treatment<span> of MM, such as proteasome inhibitors, </span></span>immunomodulatory drugs<span>, monoclonal antibodies, bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates. In this paper we briefly highlight essential clinical elements relating to proteasome inhibitors, such as </span></span>bortezomib<span>, carfilzomib and </span></span>ixazomib<span><span>. Studies suggest that the early use of immunotherapy<span> may improve outcomes significantly. Therefore, in our review we specifically focus on the combination therapy of proteasome inhibitors with novel immunotherapies and/or transplant. A high number of patients develop PI resistance. Thus, we also review new generation PIs, such as marizomib, </span></span>oprozomib (ONX0912) and </span></span>delanzomib (CEP-18770) and their combinations with immunotherapies.</span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"61 ","pages":"Article 101100"},"PeriodicalIF":6.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma\",\"authors\":\"David Kegyes ,&nbsp;Diana Gulei ,&nbsp;Rares Drula ,&nbsp;Diana Cenariu ,&nbsp;Bogdan Tigu ,&nbsp;Delia Dima ,&nbsp;Alina Tanase ,&nbsp;Sorina Badelita ,&nbsp;Anca-Dana Buzoianu ,&nbsp;Stefan Ciurea ,&nbsp;Gabriel Ghiaur ,&nbsp;Evangelos Terpos ,&nbsp;Aaron Ciechanover ,&nbsp;Hermann Einsele ,&nbsp;Ciprian Tomuleasa\",\"doi\":\"10.1016/j.blre.2023.101100\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of all neoplastic diseases. Nowadays, clinicians have a broad arsenal of </span>drugs<span><span><span><span><span> at their disposal for the treatment<span> of MM, such as proteasome inhibitors, </span></span>immunomodulatory drugs<span>, monoclonal antibodies, bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates. In this paper we briefly highlight essential clinical elements relating to proteasome inhibitors, such as </span></span>bortezomib<span>, carfilzomib and </span></span>ixazomib<span><span>. Studies suggest that the early use of immunotherapy<span> may improve outcomes significantly. Therefore, in our review we specifically focus on the combination therapy of proteasome inhibitors with novel immunotherapies and/or transplant. A high number of patients develop PI resistance. Thus, we also review new generation PIs, such as marizomib, </span></span>oprozomib (ONX0912) and </span></span>delanzomib (CEP-18770) and their combinations with immunotherapies.</span></p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":\"61 \",\"pages\":\"Article 101100\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23000619\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000619","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

多发性骨髓瘤(MM)是一种恶性浆细胞疾病,约占所有肿瘤疾病的1.8%。如今,临床医生拥有广泛的治疗MM的药物库,如蛋白酶体抑制剂、免疫调节药物、单克隆抗体、双特异性抗体、CAR T细胞疗法和抗体-药物偶联物。在这篇文章中,我们简要强调了与蛋白酶体抑制剂有关的重要临床因素,如硼替佐米、卡非佐米和伊沙唑米。研究表明,早期使用免疫疗法可能会显著改善疗效。因此,在我们的综述中,我们特别关注蛋白酶体抑制剂与新型免疫疗法和/或移植的联合治疗。大量患者出现PI耐药性。因此,我们还综述了新一代PIs,如马里佐米、奥洛佐米(ONX0912)和德兰佐米(CEP-18770)及其与免疫疗法的组合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma

Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal for the treatment of MM, such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates. In this paper we briefly highlight essential clinical elements relating to proteasome inhibitors, such as bortezomib, carfilzomib and ixazomib. Studies suggest that the early use of immunotherapy may improve outcomes significantly. Therefore, in our review we specifically focus on the combination therapy of proteasome inhibitors with novel immunotherapies and/or transplant. A high number of patients develop PI resistance. Thus, we also review new generation PIs, such as marizomib, oprozomib (ONX0912) and delanzomib (CEP-18770) and their combinations with immunotherapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信